Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3535-3539

  Yamaguchi, Kentaro ^a   Nakagawa, Satoru ^a   Yabusaki, Hiroshi ^a   Nashimoto, Atsushi ^a  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 FU; Cisplatin; Combination chemotherapy; Gastric cancer; Paclitaxel

Indexed keywords

CHLORPHENIRAMINE MALEATE; CISPLATIN; DEXAMETHASONE; FAMOTIDINE; FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; MALE; NEUTROPENIA; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; STOMACH NEOPLASMS;

EID: 35348971985     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, Testa E, Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G, Cellerino R and Catalano G: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15: 3313-3319, 1997.
2. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000.
3. Nakajima T: Gastric cancer treatment guidelines in Japan. Gastric Cancer 5: 1-5, 2002.
4. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R and Mansfield PF: Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274, 1998.
5. Yamada Y, Shirao K, Ohtsu A Boku N, Hyodo I, Saitoh H, Miyata Y and Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12: 1133-1137, 2001.
6. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R and Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21: 416-419, 1998.
7. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L Donegan J, Pazdur R, Reed C and Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826-1834, 1998.
8. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi K: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710, 1996.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid rumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
10. Japanese classification of gastric carcinoma - 2nd English edition - response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 4: 1-8, 2001.
11. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, National Cancer Institute, National Institute of Health, Department of Health and Human service, March 31, 2003.
12. Tsuji A Morita S, Horimi T, Takasaki M, Takahashi I and Shirasaka T: Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. Gan To Kagaku Ryoho 27(Suppl 2): 528-534, 2000 (in Japanese).
13. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K and Toge T: A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 15: 921-926, 1999.
14. Kim R, Nishimoto N, Inoue H, Yoshida K and Toge T: An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. J Infect Chemother 6: 222-228, 2000.
15. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y and Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 57: 202-210, 1999.
16. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000.
17. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
18. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
19. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J and Seeber S: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92-97, 1995.
20. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH and Kim JS: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85: 295-301, 1999.
21. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L and Bokemeyer C: A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83: 458-462, 2000.
22. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R and Philip PA: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 26: 37-41, 2003.
23. Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ and Wanebo H: Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 9: 53-57, 1999.
24. Lokich JJ, Sonneborn H, Anderson NR, Bern MM, Coco FV, Dow E and Oliynyk P: Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 85: 2347-2351, 1999.
25. Gotoh M, Kawabe S and Takiuchi H: S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Gan To Kagaku Ryoho 33(Suppl 1): 91-94, 2006 (in Japanese).
26. Mochiki E, Ohno T, Kamiyama Y, Aihara R, Haga N, Ojima H, Nakamura J, Ohsawa H, Nakabayashi T, Takeuchi K, Asao T and Kuwano H: Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 95: 1642-1647, 2006.
27. Takahashi T, Saikawa Y, Yoshida M, Kitagawa Y, Otani Y, Kubota T, Kumai K and Kitajima M: A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer. Anticancer Res 26: 1631-1635, 2006.
28. Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J, Yamaguchi T, Sugihara M, Ina K, Kusugami K and Goto S: A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 25: 1297-1301, 2005.
29. Iwase H, Shimada M, Tsuzuki T, Okeya M, Kobayashi K, Hibino Y, Watanabe H and Goto H: A phase I study of S-1 administration and a 24-h infusion of cisplatin plus paclitaxel in patients with advanced gastric cancer. Anticancer Res 26: 1605-1610, 2006.
30. Polyzos A, Tsavaris N, Kosmas C, Polyzos K, Giannopoulos A, Felekouras E, Nikiteas N, Kouraklis G, Griniatsos J, Safioleas M, Stamatakos M, Pikoulis E, Papachristodoulou A and Gogas H: Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin. Anticancer Res 26: 3749-3753, 2006.
31. Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, Kwon KY, Do YR, Ryoo HM, Bae SH, Park KU, Kim MK, Lee KH, Hyun MS, Chung HY and Yu W: Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. J Korean Med Sci 20: 966-970, 2005.